Xigduo XR is a combination medication used to address multiple clinical needs. It is commonly used as part of a therapeutic regimen across domains where additional symptomatic support and chronic disease management are needed. Its therapeutic applications include playing a role in managing blood sugar levels in conditions characterized by periods of heightened symptoms, supporting cardiovascular health in high-risk patients, and assisting with maintaining kidney function.

---

Symptomatic Domains

This medication is applicable within clinical settings that involve acute or disruptive symptom patterns and is relevant when supportive symptom management is appropriate. It addresses symptoms related to systemic imbalance and those that create noticeable physiological strain, particularly those associated with chronic conditions. The core benefit provided is that it contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

“It assists with maintaining functional stability in conditions presenting with systemic or localized discomfort.”

Quick Fact: Supports in managing Physiological Strain

---

Core Therapeutic Areas

The main uses involve: Blood Sugar Management, where it plays a role in managing blood sugar levels; and Cardiovascular and Kidney Support, where it is applied in scenarios requiring additional management of discomfort in conditions related to heart and kidney function.

This section summarizes the official population eligibility and non-eligibility for Xigduo XR, strictly based on regulatory documents.

Contraindications and Absolute Exclusions

The medicine is contraindicated (must not be used) for patients with:

• Severe renal impairment (estimated eGFR below 30 mL/min/1.73 m^2), end-stage renal disease, or dialysis.
• Any form of acute or chronic metabolic acidosis, including diabetic ketoacidosis or lactic acidosis.
• A history of serious hypersensitivity reaction to dapagliflozin, metformin HCl, or any other component.

Eligibility and Restricted Use

Category	Official Regulatory Status
Eligible Population	Adults and pediatric patients aged 10 years and older with Type 2 Diabetes Mellitus.
Type of Diabetes	Not recommended for Type 1 Diabetes Mellitus.
Renal Function	Not recommended if eGFR is persistently below 45 mL/min/1.73 m^2.
Hepatic Function	Avoid use in patients with hepatic impairment (liver problems).
Pregnancy/Lactation	Not recommended during the second and third trimesters of pregnancy or when breastfeeding.

Use requires caution in older adults due to a higher risk of adverse reactions related to reduced intravascular volume. The drug must be temporarily withheld before specific imaging procedures involving iodinated contrast or major surgery.

The documented interaction profile for Xigduo XR involves patterns arising from both its active components, dapagliflozin and metformin.

Pharmacokinetic and Substance Interactions

Co-administration with certain medicinal products results in increased plasma concentration of the metformin component. This occurs with drugs that reduce its renal clearance by inhibiting organic cation transporters (OCT) and multidrug and toxin extruders (MATE). Specific examples documented in regulatory sources include Ranolazine and Cimetidine. The metformin component also interferes with Vitamin B12 absorption, necessitating monitoring. Excessive alcohol intake is formally documented as a contraindication due to its potentiation of the risk for lactic acidosis.

Pharmacodynamic Interactions and Restrictions

Combining Xigduo XR with other agents can lead to additive effects on glucose control and fluid balance. When taken with Insulin or Sulfonylureas, there is an officially documented increased risk of hypoglycemia. Concurrently using the medicine with Diuretics or blood pressure-lowering agents may lead to intravascular volume contraction, increasing the risk of symptomatic hypotension or acute renal injury. Carbonic Anhydrase Inhibitors are noted to increase the risk of metformin-associated lactic acidosis. Finally, medical procedures involving iodinated contrast media require the medicine to be temporarily withheld for a specific period before and after administration due to the potential for reduced renal function leading to metformin accumulation.

The mechanism of Xigduo XR involves the distinct and complementary actions of its two components, Dapagliflozin and Metformin, which target different glucose regulatory systems.

Modulating Renal Glucose Excretion

Dapagliflozin acts as a highly selective inhibitor of the Sodium-Glucose Co-transporter 2 ( SGLT2) located in the proximal renal tubules . By blocking this transporter, the drug prevents the reabsorption of most filtered glucose; this process leads to glucose being expelled in the urine (glucosuria). This insulin-independent molecular cascade establishes a physiological state of increased systemic glucose clearance.

Regulating Hepatic Glucose Production

Metformin initiates its action by mildly inhibiting mitochondrial Complex I in the liver, which activates the central metabolic sensor, AMP-activated protein kinase (AMPK) . This AMPK activation suppresses the transcription and activity of enzymes necessary for the liver to produce glucose (gluconeogenesis). This pathway decreases the net amount of glucose released by the liver into the systemic circulation.

Complementary Multi-Pathway Synergy

The combination operates by simultaneously targeting two core mechanisms of glucose dysregulation: Dapagliflozin increases glucose clearance via the kidney, while Metformin decreases glucose production in the liver and improves peripheral utilization (insulin-sensitizing effect). This dual, multi-organ approach facilitates a robust and parallel influence on systemic glucose balance through distinct mechanistic pathways.

Xigduo XR is an extended-release (XR) tablet formulated for oral administration and is generally taken once daily in the morning with food. The tablets must be swallowed whole and should never be crushed, cut, or chewed to maintain the drug’s extended-release properties. Dosage is individualized based on a patient’s current treatment regimen, but it cannot exceed the maximum recommended daily dosage of 10 mg dapagliflozin and 2,000 mg of metformin HCl extended-release.

---

Standard Dosing and Procedural Rules

For patients newly initiating the dapagliflozin component for glycemic control, the standard starting dose is 5 mg once daily. For approved adult indications related to heart failure and chronic kidney disease, the dapagliflozin dosage is typically 10 mg once daily. The medication is approved for use in pediatric patients aged 10 years and older for glycemic control.

A key administration rule involves renal function assessment. No dosage adjustment is required for patients with an estimated glomerular filtration rate (eGFR) 45 mL/min/1.73 m^2. However, initiation is not recommended when eGFR falls between 30 and 45 mL/min/1.73 m^2, and the medication is contraindicated below 30 mL/min/1.73 m^2.

In procedural contexts, the medication must be withheld for at least three days prior to major surgery or procedures associated with prolonged fasting, and often requires temporary discontinuation prior to iodinated contrast imaging. This structured approach ensures adherence to the specific constraints of the fixed-dose, extended-release combination.

Xigduo XR: Recent Clinical Evidence

The fixed-dose combination of dapagliflozin and metformin extended-release (XR) is supported by a clinical development program that evaluated the co-administration of the two agents in adults with Type 2 Diabetes Mellitus (T2DM).

---

Glycemic Control

Studies investigated the effect of the two drugs used together, both as initial therapy and as add-on therapy for individuals whose blood sugar was not adequately controlled on metformin alone.

Study Population	Primary Findings (HbA1c)
Initial Combination Therapy (Treatment-Naïve Patients)	The combination was studied against either agent alone. Research showed a significantly greater reduction in glycosylated hemoglobin (HbA1c) levels compared to monotherapy after 24 weeks.
Add-on to Metformin	In patients whose T2DM was inadequately controlled on metformin alone, the addition of dapagliflozin resulted in clinically relevant and statistically significant further reductions in HbA1c compared to placebo after 24 weeks.

---

Secondary Measures and Bioequivalence

Clinical trials examined several secondary outcomes beyond blood sugar control. Findings generally documented progressive reductions in fasting plasma glucose (FPG) and body weight compared to baseline or to control groups over the study periods. A decrease in systolic blood pressure was also observed in some studies.

While specific clinical trials were not conducted using the fixed-dose combination tablet itself, bioequivalence studies in healthy adults demonstrated that the combination tablet provided comparable absorption of the active ingredients (dapagliflozin and metformin XR) to that achieved when the two components were taken as separate, co-administered tablets.

Key Studies & References

1. Study Details | NCT03710460 | Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity (Pivotal Trial data used for combination efficacy)
2. Investigational Compound Dapagliflozin with Metformin Extended-Release (XR) as Initial Combination Therapy Significantly Improved Blood Sugar Control in Previously-Untreated Adult Type 2 Diabetes Patients with High Blood Sugar Levels (Initial Combination RCT Summary)

Common questions about Xigduo XR (FAQ)

---

Q: What happens if I miss a dose of Xigduo XR?

If a dose is missed, official guidance is to take it as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose should be skipped entirely. Official product information states that two doses should not be taken at the same time to compensate for a missed dose.

---

Q: How long does it take for Xigduo XR to start working?

Xigduo XR is designed as a once-daily, extended-release medication. According to pharmacokinetic studies, the two active components reach their highest concentrations in the bloodstream at different times—one component peaks in about two hours, and the other peaks between four and eight hours after administration. This design is intended to provide sustained control of blood sugar levels.

---

Q: How long can I store Xigduo XR?

The medicine must be stored at a Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with minor temperature fluctuations permitted. Official product labeling does not typically provide a separate 'use by' date once the bottle is opened; reference the expiration date printed on the packaging.

---

Q: Can I take Xigduo XR if I am pregnant?

Regulatory documents state that use of this medicine is not recommended during the second and third trimesters of pregnancy. Limited data is available for the first trimester. If pregnancy is detected while taking Xigduo XR, the medication should be discontinued based on regulatory information.

---

Q: What class of drug is Xigduo XR?

Xigduo XR is a fixed-dose combination medication. It combines two distinct types of agents: a Sodium-Glucose Co-transporter 2 ( SGLT2) inhibitor (Dapagliflozin) and a Biguanide (Metformin Hydrochloride). Together, these agents target different mechanisms to help improve blood sugar control.

---

Q: What are the most common side effects of Xigduo XR?

Based on official clinical trial data, the most frequently reported adverse reactions include female genital mycotic (yeast) infections, nasopharyngitis (symptoms of a common cold), urinary tract infections, diarrhea, and headache.

---

Q: Is Xigduo XR used to treat Type 1 or Type 2 Diabetes?

According to the official Indications and Usage information, Xigduo XR is approved to improve blood sugar control in adults with Type 2 Diabetes Mellitus. Regulatory information confirms it is not recommended for the treatment of people with Type 1 Diabetes Mellitus.

How to Store and Dispose of Xigduo XR

Xigduo XR tablets must be stored according to regulatory specifications to ensure stability and effectiveness.

Storage Requirements

The required storage environment is Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions are permitted between 15 C and 30 C (59 F and 86 F). The medication must be kept out of the sight and reach of children and stored in its original packaging in a cool, dry place. The official shelf-life of 24 months is maintained under these specified conditions.

Disposal Instructions

When Xigduo XR tablets are no longer needed or have expired, they must be properly discarded. Regulatory guidelines advise that the product should not be disposed of in general household trash, drains, or sewers. Unused or expired medication should be returned to a pharmacist or collected through approved pharmaceutical waste programs.